Oral Session 2-11B AML: Clinical Study (2)

[OS2-11B-3] Risk-adapted ATRA and anthracycline-based treatment for APL: a multicenter study by the FBMTG

Tomohiko Kamimura¹, Ken Takase², Koji Kato³, Takatoshi Aoki¹, Tetsuya Eto⁴, Ryosuke Ogawa⁵, Tomoaki Fujisaki⁶, Naoyuki Uchida⁷, Motoaki Shiratsuchi⁸, Kazuki Tanimoto⁹, Yuju Ohno¹⁰, Hiromi Iwasaki², Koji Nagafuji¹¹, Takanori Teshima¹², Shuichi Taniguchi⁷, Toshihiro Miyamoto³, Koichi Akashi³, Mine Harada¹³ (1.Department of Hematology, Harasanshin Hospital, Fukuoka, Japan, 2.Department of Hematology, National Kyushu Medical Center, Fukuoka, Japan, 3.Department of Hematology, Kyushu University Hospital, Fukuoka Japan, 4.Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan, 5.Department of Hematology, JCHO Kyushu Hospital, Kita-Kyushu, Japan, 6.Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan, 7.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 8.3rd Deaprtment of Internal Medicine, Kyushu University Hospital, Fukuoka, Japan, 9.Department of Hematology/Oncology, Fukuoka Red Cross Hospital, Fukuoka, Japan, 10.Department of Hematology, Kitakyushu City Hospital, Fukuoka, Japan, 11.Department of Hematology/Oncology, Kurume University Hospital, Kurume, Japan, 12.Department of Hematology, Hokkaido University Hospital, Sapporo, Japan, 13.Medical Center for Karatsu-Higashimatsuura Medical Association, Karatsu, Japan)